A ‘Revolution’ in drugging the undruggable hits a speed bump but motors on
Listen now
Description
Though Revolution Medicines Inc.’s RAS inhibitor RMC-4630 failed to show efficacy in two early-stage combination trials, the company is moving forward with the candidate, its lead asset, partnered with Sanofi SA. Mark Goldsmith, Revolution’s president, CEO and chairman joined the BioWorld Insider Podcast to discuss the challenges and progress in other experiments.
See acast.com/privacy for privacy and opt-out information.
More Episodes
Chris Barden, a co-managing partner at MPM Bioimpact who manages the firm’s Bioimpact Equities and Oncology Impact funds, shares her insights into the upcoming American Society of Clinical Oncology (ASCO) conference in Chicago. She talks about the major trends in oncology, including development...
Published 05/30/24
Published 05/30/24
A non-traditional route for financing has been the path to success for Fibrobiologics Inc. In the newest BioWorld Insider podcast, CEO Pete O’Heeron offers insight into the company’s unusual path to a Nasdaq listing in January. SPACs, reverse mergers and traditional IPOs weren’t attractive enough...
Published 05/15/24
Artwork or description wrong?
Request an update »
Updates may take a few minutes.
Do you host a podcast?
Track your ranks and reviews from Spotify, Apple Podcasts and more.
See hourly chart positions and more than 30 days of history.
Get Chartable Analytics »
See hourly chart positions and more than 30 days of history.
